

02/SEP 2004

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
25 September 2003 (25.09.2003)

PCT

(10) International Publication Number
WO 03/078398 A1(51) International Patent Classification: C07D 215/08,
A61K 31/47, A61P 15/00, C07D 413/14, 413/06, 417/06,
498/04, 241/44, 409/06, 401/06, 405/06

(21) International Application Number: PCT/GB03/01042

(22) International Filing Date: 12 March 2003 (12.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0206219.8 15 March 2002 (15.03.2002) GB(71) Applicant (for all designated States except US): FER-
RING BV [NL/NL]; Polaris Avenue 144, NL-2132 JX
Hoofddorp (NL).


(72) Inventors; and

(75) Inventors/Applicants (for US only): ROE, Michael,

Bryan [GB/GB]; 1B Cambridge Road, Southampton
SO14 6RB (GB). BATT, Andrzej, Roman [GB/GB];
41 Kent Road, Southampton SO17 2LJ (GB). EVANS,
David, Michael [GB/GB]; 114 Adelaide Road, Southamp-
ton SO17 2HX (GB). PITT, Gary, Robert, William
[GB/GB]; Old Pump House, Rivermead, Idmiston, Salis-
bury, Wiltshire SP4 0AR (GB). ROOKER, David, Philip
[GB/GB]; 8 Lake Grove Road, New Milton, Hampshire
BH25 5LA (GB).(74) Agent: BATES, Philip, Ian; Reddie & Grose, 16
Theobalds Road, London WC1X 8PL (GB).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: NON-PEPTIDE GnRH ANTAGONISTS



1

(57) Abstract: Compounds according to general formula 1, wherein A¹ - A³ are selected from A⁵ and A⁶ where A⁵ is either =CR¹³ or =N- and A⁶ is -NR¹⁴-, -O- or -S-; A⁴ is either a covalent bond or A⁵, provided that when A⁴ is a covalent bond one of A¹ - A³ must be A⁶ and the other two must be A⁵ and when A⁴ is A⁵ then all of A¹ - A³ must be A⁵; R¹ is selected from H, NHY¹ and COY², in which case R² is H, or R¹ and R² may both be methyl or together represent =O; R³, R⁴ and R⁵ are each independently selected from H and lower alkyl groups; R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹ and R¹² are each independently selected from H, lower alkyl groups, NH₂, halogens (F, Cl and Br) O-alkyl, CH₂NMe₂ and CF₃; R¹³ is selected from H, F, Cl, Br, NO₂, NH₂, OH, Me, Et, OMe, NMe₂ and CF₃; R¹⁴ is selected from H, methyl and ethyl; W is selected from =CH- and =N-; X is selected from CH₂, O, S, SO₂, NH and N-lower alkyl; Y¹ is selected from CO-lower alkyl, CO(CH₂)_bY³, CO(CH₂)_bCOY³ and CO(CH₂)_bNHCOY³, where b is 1-3; Y² is selected from OR¹⁵, NR¹⁶R¹⁷ and NH(CH₂)_cCOY³, where c is 1-3; Y³ is selected from OR¹⁵ and NR¹⁶R¹⁷; R¹⁵ is selected from H, lower alkyl and (CH₂)_aR¹⁶, where a is 0-4; R¹⁶ and R¹⁷ are each independently selected from H, lower alkyl and (CH₂)_bR¹⁶ or together are -(CH₂)₂-Z-(CH₂)₂-; R¹⁸ is OH a phenyl group or an aromatic heterocycle selected from pyridyl, pyrimidinyl, pyrazinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl and thiadiazolyl, each of which may optionally have a lower alkyl group substituent; and Z is selected from O, CH₂, S, SO₂, NH and N-lower alkyl, are new. They are useful in the treatment of breast and prostate cancer, endometriosis and benign prostate hyperplasia, in the regulation of fertility, and in *in vitro* fertilisation.

WO 03/078398 A1



162162



ACTION